In a major setback, the Indian Patent Office denied a patent to an anti-cancer drug Abraxane manufactured by US-Based Abraxis BioSciences. Here we will discuss the decision given by IPO at the backdrop of the arguments advanced by the respective…
On June 12th, 2014, Elon Musk, CEO and Chief Product Architect of electric car company Tesla Motors announced that Tesla Motors will let other companies use its inventions under an open-source inspired agenda at the company. This is how Elon…
As per the sources, the court in the Odisha capital, Bhuvaneshwar has admitted a petition challenging Aamir Khan Production’s plans to use ‘Satyamev Jayate’, the national motto of India, as a business brand under which it is proposed to sell…
Oracle vs. Google is truly one of the most amazing IP battles that I have personally observed in the recent past. What millions of developers and customers would have literally thought to have been considered open Application Programming Interfaces (APIs)…
Manish Kumar, the intern at Khurana and Khurana, Advocates and IP Attorneys, looks at the ‘fee-shifting’ paradigm in US Patent Act in light of US Supreme Court's recent judgments. The US Supreme Court, in its two recent judgments, has re-instituted…
Introduction A lot has been discussed on the Novartis ruling indicating much higher standards of patentability under Indian law under section 3d. The ruling decided that any new form of known compound (in medicine) would be patentable only if there…
Takshasheel Bouddha, an intern at Khurana and Khurana Advocates and IP Attorneys, analyses the case, M/s Aditi Manufacturing Company v/s Mr. Bharat Bhogilal Patel &The Controllers of Patents & Designs. This judgment is with respect to Section 64 of the…
In recent years, trademark registries and courts have grappled with applications for silhouettes, shapes, scents, textures, short cartoons, single colors, body movements, etc as trademarks. This invasion of the unconventional is due to the abstract nature of the legal definition…
In a positive development for US drug giant Pfizer, the country’s Intellectual Property Appellate Board (IPAB) has issued an interim stay on an order stated by the Indian Patent Office removing a patent of Pfizer, for its extended-release drug Tolterodine…
There has been limited judicial consideration of how patent law applies to pharmaceutical inventions in India. Little specific guidance is available to patent examiners in assessing whether a particular pharmaceutical invention satisfies the requirements for patentability. The absence of judicial…